Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2024 09:00 ET | Source: ProLynx LLC

ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors

SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled “Could...
September 05, 2019 09:00 ET | Source: ProLynx LLC

ProLynx announces publication and initiation of patient recruitment for a trial of once-monthly treatment of diabetes in cats

SAN FRANCISCO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Today, ProLynx announced publication of data supporting therapy of Type 2 diabetes in cats with PLX039, a GLP-1 receptor agonist that can be...
May 02, 2019 06:00 ET | Source: ProLynx LLC

ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye

SAN FRANCISCO, May 02, 2019 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a second collaboration with Daiichi Sankyo Company, Limited to utilize its drug delivery linker technology to extend the...
August 29, 2018 09:00 ET | Source: ProLynx LLC

ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye

SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for...
April 03, 2018 09:00 ET | Source: ProLynx LLC

ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system

SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...
September 25, 2017 09:00 ET | Source: ProLynx LLC

ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists

SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control...